Effect of Transcutaneous Vagal Stimulation (TVS) on Endothelial Function and Arterial Stiffness in HFrEF



Status:Recruiting
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - 80
Updated:7/18/2018
Start Date:December 4, 2017
End Date:May 30, 2019
Contact:Tarun Dasari, MD,MPH
Email:tdasari@ouhsc.edu
Phone:4052714742

Use our guide to learn which trials are right for you!

Effect of Transcutaneous Vagal Stimulation (TVS) on Endothelial Function and Arterial Stiffness in Patients With Heart Failure With Reduced Ejection Fraction

Heart failure (HF) is the leading cause of hospitalization in the US. Endothelial
dysfunction, characterized by the decreased vasodilatory capacity of the vascular
endothelium, is rampant in atherosclerotic diseases such as coronary artery disease and also
in HF. Endothelial dysfunction also correlates with HF severity, progression, and mortality.
It is postulated that endothelial dysfunction may in part be due to enhanced sympathetic
drive, diminished parasympathetic drive, chronic inflammatory state thereby leading to
reduced nitric oxide synthase activity in the vascular endothelium. Low-level vagus nerve
stimulation (LLVNS) is an invasive way to modulate autonomic tone. Recent experimental and
clinical data suggest that low-level transcutaneous vagal stimulation (TVS) (by stimulating
the auricular branch of the vagus nerve located at the tragus of the external ear) may
produce the same desired neuromodulator effect compared to LLVNS. The objective of this study
is to determine the impact of TVS on endothelial dysfunction and arterial stiffness. The
study population will include patients with chronic HFrEF. After performing baseline
flow-mediated dilation (FMD), laser speckle contrast imaging(LSCI) and pulse wave analysis
(PWA) testing, patients will be randomized to TVS or sham stimulation with a crossover design
at different time points. The patient randomized to TVS arm will undergo stimulation for 1
hour followed by immediate measurement of FMD,LSCI and PWA. There will be a washout period of
at least 24 hours with patient crossing over to the other arms thus serving as their
self-control.


Inclusion Criteria:

1. Patients (18 years or older) with Heart failure with reduced ejection fraction (HFrEF),
which is a history of symptomatic heart failure with left ventricular ejection fraction
(LVEF) of < 40%.

Exclusion Criteria:

1. patients in overt congestive heart failure / recent acute myocardial infarction (< 3
months) or Unstable angina

2. Active malignancy

3. Perimenopausal women and post-menopausal women on hormone supplements.

4. unilateral or bilateral vagotomy

5. Patients with bilateral upper extremity amputation

6. pregnant patients

7. End-stage renal disease

8. End-stage liver disease

9. history of recurrent vasovagal syncope, Sick sinus syndrome, 2nd- or 3rd-degree
atrioventricular (AV) block.

10. patients with clinically documented upper extremity arterial disease

11. patients with BMI>34
We found this trial at
1
site
940 NE 13th St
Oklahoma City, Oklahoma 73190
(405) 271-6458
Phone: 405-271-4742
University of Oklahoma Health Sciences Center The OU Health Sciences Center is composed of seven...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials